Fig. 3
From: Abnormal glycosylation in glioma: related changes in biology, biomarkers and targeted therapy
Biomarker and treatment. (a) The changes of glycosylation-related enzymes and cell surface glycosylation in glioma provide an important source of markers for its diagnosis, prognosis, pathological classification, and pathological diagnosis. (b) In terms of treatment, it can be achieved by regulating the expression of glycosylation-related enzymes (such as FUT8, ST6GalNAcV, β1, 4GalT V …), using glycosylation inhibitors (such as NGI-1), and targeted therapy (such as sGal-3, PTN, MK, BTP-7).